Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 363 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
75
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 3, 2026, 6:53 AM EDT
Terminated Not applicable Interventional Results available

PTNS for Female Patients Suffering From Multiple Sclerosis

NCT05422625
View directory record Official record
Conditions
Multiple Sclerosis, Overactive Bladder
Interventions
PTNS Treatment, Sham PTNS Treatment
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 3, 2026, 6:53 AM EDT
Withdrawn Not applicable Interventional

Noninvasive Spinal Cord Stimulation for Neurogenic and Idiopathic Overactive Bladder

NCT03753750
View directory record Official record
Conditions
Overactive Bladder, Incontinence, Urge, Neurogenic Bladder
Interventions
Noninvasive spinal cord stimulation
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 3, 2026, 6:53 AM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 3, 2026, 6:53 AM EDT
Active, not recruiting Not applicable Interventional

Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study

NCT05715268
View directory record Official record
Conditions
Multiple Sclerosis, Urinary Bladder, Overactive
Interventions
WeB, Standard pelvic floor physical therapy
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 3, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lidocaine Patches Prior to Percutaneous Nerve Evaluation

NCT05783219
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Fecal Incontinence
Interventions
Lidocaine patch, Placebo
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 3, 2026, 6:53 AM EDT
Completed Phase 1 Interventional

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

NCT01870037
View directory record Official record
Conditions
Overactive Bladder
Interventions
Placebo (PBS-20% sucrose), hMaxi-K
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Garden City, New York • New York, New York • Poughkeepsie, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 3, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

NCT01767519
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 3, 2026, 6:53 AM EDT
Not listed Not applicable Interventional

CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

NCT02577302
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
Device
Lead sponsor
Uro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 3, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB

NCT03017170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Dried Cranberry, Placebo Oral Capsule
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 3, 2026, 6:53 AM EDT
Not yet recruiting Phase 3 Interventional

Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder

NCT07780786
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Wearable neurostimulation system for saphenous nerve stimulation, tolterodine tartrate 4 mg extended release
Device · Drug
Lead sponsor
NinaMED Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 6:53 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

NCT05221021
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Vaginal estrogen, Mirabegron 50 MG [Myrbetriq]
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 3, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis

NCT02086188
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 3, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction

NCT01220726
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 3, 2026, 6:53 AM EDT
Completed No phase listed Observational

Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

NCT03043287
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
onabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Shreveport, Louisiana • Baltimore, Maryland • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 3, 2026, 6:53 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection

NCT03508921
View directory record Official record
Conditions
Overactive Bladder, Urinary Tract Infections
Interventions
Periprocedural Antibiotics, Extended Antibiotics, Injection of OnabotulinumtoxinA (BTX-A)
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 3, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

NCT00425100
View directory record Official record
Conditions
Overactive Bladder
Interventions
fesoterodine fumarate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
24
States / cities
Homewood, Alabama • Huntsville, Alabama • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 3, 2026, 6:53 AM EDT
Terminated Not applicable Interventional

Group Medical Visits for Latina Women With Urgency Urinary Incontinence

NCT03687164
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency, Urge Incontinence
Interventions
Group Medical Visits
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 3, 2026, 6:53 AM EDT
Active, not recruiting Not applicable Interventional

Trial for Reliability of Urodynamics SysTem

NCT05694793
View directory record Official record
Conditions
Urologic Diseases, Urodynamics
Interventions
Glean Urodynamics System
Device
Lead sponsor
Bright Uro
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Murrieta, California • San Diego, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 3, 2026, 6:53 AM EDT
Not yet recruiting Not applicable Interventional

Tensi+ for Treating Overactive Bladder

NCT07300904
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Tensi+
Device
Lead sponsor
Stimuli Technology
Industry
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Beverly Hills, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 3, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Results available

Study of V117957 in Overactive Bladder Syndrome

NCT06024642
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
V117957, Placebo
Drug
Lead sponsor
Imbrium Therapeutics
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Canoga Park, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 3, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00912964
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
82
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 3, 2026, 6:53 AM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.

NCT00645281
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
tolterodine extended release
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
96
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 3, 2026, 6:53 AM EDT
Terminated Phase 3 Interventional Results available

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

NCT02097121
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Overactive
Interventions
BOTOX®
Biological
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
8
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 3, 2026, 6:53 AM EDT